Related Experiment Video
Updated: Mar 21, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MicroRNA-21 Regulates Non-Small Cell Lung Cancer Cell Invasion and Chemo-Sensitivity through SMAD7
Background/Aims:
SMAD7 is a key inhibitor of transforming growth factor β (TGFβ) receptor signaling, which regulates the alteration of cancer cell invasiveness through epithelial-mesenchymal cell conversion. Carboplatin is a commonly used drug in the chemotherapy for non-small cell lung cancer (NSCLC). Nevertheless, the molecular mechanisms underlying its suppressive effects on the NSCLC cell invasion are not completely understood. In the current study, we addressed this question by analyzing the effects of Carboplatin on microRNA-regulated SMAD7.
Methods:
We used Carboplatin to treat NSCLC cell lines. We performed bioinformatics analyses on the binding of microRNA-21 (miR-21) to the 3'-UTR of SMAD7 mRNA, and verified the biological effects of this binding using promoter luciferase reporter assay. The effects of Carboplatin or miR-21-modification on NSCLC cell invasion were evaluated in either a transwell cell invasion assay, or a scratch wound healing assay.
Results:
We found that Carboplatin inhibited the NSCLC cell invasion, in either a transwell cell invasion assay, or a scratch wound healing assay. Moreover, Carboplatin increased the levels of SMAD7 protein, but not mRNA, in NSCLC cells, suggesting presence of post-transcriptional control of SMAD7 by Carboplatin. Furthermore, expression of miR-21 was found to be inhibited by Carboplatin, and bioinformatics analyses showed that miR-21 targeted the 3'-UTR of SMAD7 mRNA to inhibit its translation, which was confirmed by luciferase reporter assay.
Conclusion:
Carboplatin may upregulate SMAD7 through suppression of miR-21 to inhibit TGFβ receptor signaling mediated NSCLC cell invasion.
Insights
Carboplatin inhibits non-small cell lung cancer (NSCLC) invasion by increasing SMAD7 protein. This occurs through Carboplatin
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- SMAD7 is a key inhibitor of transforming growth factor β (TGFβ) signaling, crucial for epithelial-mesenchymal transition in cancer.
- Carboplatin is a standard chemotherapy for non-small cell lung cancer (NSCLC), but its precise mechanisms against invasion are unclear.
- Understanding Carboplatin's effects on microRNA-regulated pathways like SMAD7 is vital for optimizing NSCLC treatment.
Purpose of the Study:
- To investigate the molecular mechanisms by which Carboplatin affects SMAD7 expression and non-small cell lung cancer (NSCLC) cell invasion.
- To analyze the role of microRNA-21 (miR-21) in Carboplatin's regulation of SMAD7 and subsequent effects on cancer cell invasiveness.
Main Methods:
- Carboplatin treatment of NSCLC cell lines.
- Bioinformatics analysis and luciferase reporter assays to study miR-21 binding to SMAD7 3'-UTR.
- Transwell invasion and scratch wound healing assays to evaluate cell invasion and migration.
Main Results:
- Carboplatin significantly inhibited NSCLC cell invasion and migration.
- Carboplatin treatment led to increased SMAD7 protein levels, indicating post-transcriptional regulation.
- Carboplatin suppressed miR-21 expression, which directly targets SMAD7 mRNA, inhibiting its translation.
Conclusions:
- Carboplatin upregulates SMAD7 protein by suppressing miR-21, thereby inhibiting TGFβ receptor signaling.
- This miR-21/SMAD7 pathway modulation contributes to Carboplatin's anti-invasive effects in NSCLC.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

